HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer.
HMGA2
IL-6
IL-8
NF-kB
STAT3
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Oct 2021
16 Oct 2021
Historique:
received:
03
10
2021
accepted:
11
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that exhibits a high proliferation rate and early metastasis leading to a poor prognosis. HMGA2 is a DNA binding transcriptional regulator implicated in tumorigenesis. Here, we demonstrate that the
Identifiants
pubmed: 34680349
pii: cancers13205197
doi: 10.3390/cancers13205197
pmc: PMC8533747
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Med. 2014 Jun;3(3):702-9
pubmed: 24756915
Curr Probl Cancer. 2002 Sep-Oct;26(5):282-309
pubmed: 12429950
Oncotarget. 2018 Aug 24;9(66):32556-32569
pubmed: 30220965
J Clin Oncol. 2010 Apr 1;28(10):1684-91
pubmed: 20194857
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Am J Cancer Res. 2017 Feb 01;7(2):260-274
pubmed: 28337375
J Cell Biochem. 2019 Apr;120(4):5024-5032
pubmed: 30317663
Cell Cycle. 2016 Oct;15(19):2585-2592
pubmed: 27245202
J Cell Physiol. 2020 Feb;235(2):920-931
pubmed: 31241772
Int J Mol Sci. 2020 Jan 19;21(2):
pubmed: 31963852
Life Sci. 2021 Jul 1;276:119431
pubmed: 33785332
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Cancer. 2007 May 1;109(9):1721-8
pubmed: 17387718
Nat Commun. 2017 May 26;8:15584
pubmed: 28548090
Expert Opin Ther Targets. 2020 Mar 14;:1-11
pubmed: 32172636
PLoS One. 2013 Nov 11;8(11):e78728
pubmed: 24244348
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
J Cell Physiol. 2019 Aug;234(10):17714-17726
pubmed: 30825204
Genes (Basel). 2021 Feb 13;12(2):
pubmed: 33668453
Cardiovasc Res. 2010 May 1;86(2):211-8
pubmed: 20202975
Mol Cancer Res. 2013 May;11(5):494-505
pubmed: 23386688
Prostate. 2008 Sep 15;68(13):1443-9
pubmed: 18615482
J Gastrointest Cancer. 2017 Jun;48(2):156-163
pubmed: 27629422
Cancer Res. 2013 Jun 1;73(11):3470-80
pubmed: 23633491
J Cell Biol. 2006 Jul 17;174(2):175-83
pubmed: 16831886
Breast Cancer Res Treat. 2013 Apr;138(3):657-64
pubmed: 23532539
Onco Targets Ther. 2018 Apr 11;11:2063-2073
pubmed: 29695914
J Interferon Cytokine Res. 2013 Oct;33(10):563-70
pubmed: 23697558
Int J Cancer. 2008 Jul 15;123(2):348-356
pubmed: 18452175
Mol Vis. 2012;18:2420-37
pubmed: 23077401
Int J Mol Sci. 2020 Jan 06;21(1):
pubmed: 31935816
Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243
pubmed: 18980022
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
Front Physiol. 2018 Jun 26;9:776
pubmed: 29997523